RabMAb

Anti-Topoisomerase II alpha抗体[EP1102Y] (ab52934)

发表研究结果有使用 ab52934?请让我们知道,以便我们可以引用本数据表中的参考文章。

ab52934 被引用在 7 文献中.

  • Scapulatempo-Neto C  et al. Characterization of topoisomerase II a and minichromosome maintenance protein 2 expression in anal carcinoma. Oncol Lett 13:1891-1898 (2017). IHC-P ; Human . PubMed: 28454340
  • Lopez-Mosqueda J  et al. SPRTN is a mammalian DNA-binding metalloprotease that resolves DNA-protein crosslinks. Elife 5:N/A (2016). WB ; Human . PubMed: 27852435
  • Dykhuizen EC  et al. BAF complexes facilitate decatenation of DNA by topoisomerase IIa. Nature 497:624-7 (2013). IP ; Mouse, Human . PubMed: 23698369
  • Taniai E  et al. Ochratoxin A induces karyomegaly and cell cycle aberrations in renal tubular cells without relation to induction of oxidative stress responses in rats. Toxicol Lett 224:64-72 (2013). Rat . PubMed: 24120684
  • Kimura M  et al. Involvement of multiple cell cycle aberrations in early preneoplastic liver cell lesions by tumor promotion with thioacetamide in a two-stage rat hepatocarcinogenesis model. Exp Toxicol Pathol 65:979-88 (2013). Rat . PubMed: 23474136
  • Park JS  et al. Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope. Cancer Immunol Immunother 59:747-57 (2010). PubMed: 19936747
  • Adler M  et al. Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity. Carcinogenesis 30:711-9 (2009). PubMed: 19237604

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"